Not a good buy right now for an impatient investor: the dominant trend is still bearish and there are no proprietary buy signals.
Price (1.14) is below the pivot (1.218) and sitting close to support (S1 1.103), which can allow small bounces, but the broader setup still favors downside risk.
Pattern-based outlook provided is weak (next month expectation: -15.36%), which outweighs the minor bullish MACD improvement.
Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (downtrend still intact).
Momentum: MACD histogram is positive (0.00213) and expanding, suggesting improving short-term momentum, but not enough yet to reverse the larger trend.
RSI(6): 27.67 (oversold/near-oversold), which can support a short-lived bounce, but oversold conditions can persist in downtrends.
Levels: Pivot 1.218 (overhead), resistance at 1.332 then 1.403; support at 1.103 then 1.032. With price at 1.14, it’s still in the lower range and below pivot.
Probabilistic/candlestick analog: expected small gains near-term (next week +2.2%) but notable projected weakness over the next month (-15.36%), reinforcing a “not-now” entry.
Positive Catalysts
Technical: RSI near oversold + positive/expanding MACD can trigger a short-term relief bounce.
Flows: Hedge funds and insiders are neutral (no recent heavy selling pressure signaled by these datasets).
Neutral/Negative Catalysts
indicates the primary trend is still down.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no YoY growth; effectively pre-revenue).
Profitability: Net income -20.94M (reported as improved YoY), but losses remain very large.
EPS: -1.12 (reported as improved YoY), still deeply negative.
Takeaway: Financial profile looks like a development-stage company with continuing substantial losses; the “improvement YoY” does not yet translate into a durable, investable growth trend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target data provided in the dataset, suggesting limited/absent Wall Street coverage.
Wall Street pros/cons view (based on available info):
Pros: If coverage emerges or a catalyst appears, micro/small-cap biotech/pharma names can re-rate quickly.
Cons: Lack of coverage + pre-revenue financials + persistent large losses typically reduce institutional confidence and can keep pressure on the stock.
Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
Low
12
Averages
12
High
12
Current: 1.110
Low
12
Averages
12
High
12
Brookline
Buy
upgrade
$12 -> $20
AI Analysis
2025-09-24
Reason
Brookline
Price Target
$12 -> $20
AI Analysis
2025-09-24
upgrade
Buy
Reason
Brookline raised the firm's price target on Medicus Pharma to $20 from $12 and keeps a Buy rating on the shares. The firm is updating its model following completion of aquisition of Antev Limited. Medicus acquired 98.6% of Antev for $75M, which includes $2.97M in cash and 1,603,164 common shares of Medicus, plus $65M in contingent payments tied to potential future Teverelix Phase 2 trial data and New Drug Application approvals. Brookline is including the potential of Teverelix in Acute Urinary Retention in its model, but does not include the potential for Teverelix in prostate cancer in its model and expects to add it to the model following Phase 2 data.
D. Boral Capital
Jason Kolbert
Buy
maintain
$14 -> $27
2025-05-12
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14 -> $27
2025-05-12
maintain
Buy
Reason
D. Boral Capital analyst Jason Kolbert raised the firm's price target on Medicus Pharma to $27 from $14 and keeps a Buy rating on the shares after the company signed a binding letter of intent to acquire Antev. This acquisition adds "significant strategic value" by bringing in Teverelix, a next-generation GnRH antagonist with strong clinical rationale and late-stage readiness, the analyst tells investors in a research note. The firm says Teverelix addresses two large, underserved markets - acute urinary retention recurrence prevention and advanced prostate cancer in patients with high cardiovascular risk. D. Boral views the transaction as a "savvy, de-risked pipeline expansion that materially enhances Medicus' near-commercial portfolio and positions the company for accelerated value creation."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDCX
